Multiples Private Equity led consortium invests Rs 6,850 M in BDR Pharma

The company will selectively pursue inorganic opportunities to build scale

Multiples Private Equity has announced an investment of Rs 6,850 million, along with a few other marquee financial investors, for a ~9.3 per cent stake in BDR Pharmaceuticals International.


The consortium of investors participating along with Multiples include institutional investors such as the investment arm of QRG Invest (Havells Family Office), and high networth individuals Nishant Agarwal of Avighna Group, and Mallika Srinivasan of TAFE.

The funds will be used by the company to build additional research and development capabilities in current and emerging areas, accelerate investments in manufacturing capacity expansion and enhance the degree of vertical integration. The company will also selectively pursue inorganic opportunities to build scale.

Manish Gaur, MD and Head of Healthcare at Multiples, said, “Multiples is thrilled to be the first PE partner for the Company, and we look forward to working closely with the leadership of BDR Pharma to unlock its full potential and create value for all stakeholders.” 

Dharmesh Shah, CMD, BDR Pharma said, “It is our pleasure to partner Multiples, as our first PE investor. Multiples is an active investor in the pharmaceuticals sector and have a strong track record of partnering with visionary entrepreneurs and management teams in helping them in their transformation journeys. We are looking forward to accelerating our growth journey with trusted investors having a deep understanding of the sector, and regulatory environment and who bring first-hand experience in working with innovative, high-growth companies.”

Support us in our endeavor to bring you Advertisement free content.
Choose your options to donate or subscribe.


Related Articles

Back to top button